xanthine has been researched along with Epilepsy in 2 studies
7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.
9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Their biomarker potential for seizures and epilepsy in peripheral blood has, however, not yet been investigated." | 1.62 | Elevated blood purine levels as a biomarker of seizures and epilepsy. ( Alves, M; Beamer, E; Conte, G; Dale, N; de Diego-Garcia, L; Delanty, N; El-Naggar, H; Engel, T; Henshall, DC; Khalil, M; Lacey, A; Rosenow, F; Tian, F, 2021) |
| "In multiple sclerosis, myelopathy, stroke, epilepsy and viral meningitis glutamate, hypoxanthine, xanthine, and uric acid are increased 2-3-fold compared to controls." | 1.30 | Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. ( Kempski, OS; Lowitzsch, K; Stover, JF, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beamer, E | 1 |
| Lacey, A | 1 |
| Alves, M | 1 |
| Conte, G | 1 |
| Tian, F | 1 |
| de Diego-Garcia, L | 1 |
| Khalil, M | 1 |
| Rosenow, F | 1 |
| Delanty, N | 1 |
| Dale, N | 1 |
| El-Naggar, H | 1 |
| Henshall, DC | 1 |
| Engel, T | 1 |
| Stover, JF | 1 |
| Lowitzsch, K | 1 |
| Kempski, OS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for xanthine and Epilepsy
| Article | Year |
|---|---|
Elevated blood purine levels as a biomarker of seizures and epilepsy.
Topics: Adenosine; Adult; Animals; Biomarkers; Case-Control Studies; Epilepsy; Humans; Hypoxanthine; Inosine | 2021 |
Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases.
Topics: Adult; Albumins; Central Nervous System Diseases; Cerebrovascular Disorders; Chromatography, High Pr | 1997 |